Cargando…

Impact of Infections in Patients Receiving Pembrolizumab-Based Therapies for Non-Small Cell Lung Cancer

SIMPLE SUMMARY: Infections are reported in up to 19% of pembrolizumab treated patients across clinical trials and in 7–100% in the standard of care population receiving various immune checkpoint inhibitor therapies. Risk factors for infection development remains controversial but among them include...

Descripción completa

Detalles Bibliográficos
Autores principales:	Burns, Ethan A., Gee, Kelly, Kieser, Ryan B., Xu, Jiaqiong, Zhang, Yuqi, Crenshaw, Aubrey, Muhsen, Ibrahim N., Mylavarapu, Charisma, Esmail, Abdullah, Shah, Shivan, Umoru, Godsfavour, Sun, Kai, Guerrero, Carlo, Gong, Zimu, Heyne, Kirk, Singh, Monisha, Zhang, Jun, Bernicker, Eric H., Abdelrahim, Maen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9817839/ https://www.ncbi.nlm.nih.gov/pubmed/36612078 http://dx.doi.org/10.3390/cancers15010081

Ejemplares similares

Case report: Efficacy and safety of regorafenib plus fluorouracil combination therapy in the treatment of refractory metastatic colorectal cancer
por: Haque, Emaan, et al.
Publicado: (2022)

Hepatitis B Virus Reactivation in Cancer Patients Treated With Immune Checkpoint Inhibitors
por: Burns, Ethan A., et al.
Publicado: (2021)

Pancreatic head vs pancreatic body/tail cancer: Are they different?
por: Sun, Kai, et al.
Publicado: (2022)

Immunotherapy as a Neoadjuvant Therapy for a Patient with Hepatocellular Carcinoma in the Pretransplant Setting: A Case Report
por: Abdelrahim, Maen, et al.
Publicado: (2022)

Gemcitabine Plus Cisplatin Versus Non-Gemcitabine and Cisplatin Regimens as Neoadjuvant Treatment for Cholangiocarcinoma Patients Prior to Liver Transplantation: An Institution Experience
por: Abdelrahim, Maen, et al.
Publicado: (2022)

Incidence and outcome of immune checkpoint-induced pneumonitis in oncology patients with history of pulmonary disease
por: Allen, Emily, et al.
Publicado: (2023)

Pancreatic Tumorigenesis: Precursors, Genetic Risk Factors and Screening
por: Badheeb, Mohamed, et al.
Publicado: (2022)

Gemcitabine and Cisplatin as Neo-Adjuvant for Cholangiocarcinoma Patients Prior to Liver Transplantation: Case-Series
por: Abdelrahim, Maen, et al.
Publicado: (2022)

Immune Checkpoint Inhibitors for Solid Tumors in the Adjuvant Setting: Current Progress, Future Directions, and Role in Transplant Oncology
por: Abboud, Karen, et al.
Publicado: (2023)

Recent Trends and Advancements in the Diagnosis and Management of Gastric Cancer
por: Haque, Emaan, et al.
Publicado: (2022)

Newest Therapies for Cholangiocarcinoma: An Updated Overview of Approved Treatments with Transplant Oncology Vision
por: Zhang, Yuqi, et al.
Publicado: (2022)

Diffuse Cerebral Edema and Impending Herniation Complicating Hepatic Encephalopathy in Hereditary Hemorrhagic Telangiectasia
por: Mylavarapu, Charisma, et al.
Publicado: (2022)

Acquired haemophilia as a paraneoplastic manifestation of pancreatic cancer
por: Arain, Abeer, et al.
Publicado: (2020)

Triple-Regimen of Vemurafenib, Irinotecan, and Cetuximab for the Treatment of BRAF(V600E)-Mutant CRC: A Case Report and Review
por: Cho, Su Min, et al.
Publicado: (2021)

Chemotherapy rechallenge in metastatic colon cancer: A case report and literature review
por: Reddy, Tejaswini Parlapalle, et al.
Publicado: (2020)

Pulmonary arterial hypertension in breast cancer patients on HER2-targeted therapy: a review of FDA Adverse Events Reporting System data
por: Umoru, Godsfavour, et al.
Publicado: (2020)

Treatment at Twilight: An Analysis of Therapy Patterns and Outcomes in Adults 80 Years and Older With Advanced or Metastatic NSCLC
por: Burns, Ethan A., et al.
Publicado: (2023)

Timeline of FDA-Approved Targeted Therapy for Cholangiocarcinoma
por: Cho, Su Min, et al.
Publicado: (2022)

Post-Marketing Analysis of Peripheral Neuropathy Burden with New-Generation Proteasome Inhibitors Using the FDA Adverse Event Reporting System
por: Mina, Syeda A., et al.
Publicado: (2021)

Utility of Cell-Free DNA Detection in Transplant Oncology
por: Reddy, Tejaswini, et al.
Publicado: (2022)

Transarterial Chemoembolization (TACE) Plus Sorafenib Compared to TACE Alone in Transplant Recipients with Hepatocellular Carcinoma: An Institution Experience
por: Abdelrahim, Maen, et al.
Publicado: (2022)

Hyperprogressive NSCLC With Two Immune-Checkpoint Inhibitors
por: Kasparian, Saro, et al.
Publicado: (2020)

Transplant Oncology: An Evolving Field in Cancer Care
por: Abdelrahim, Maen, et al.
Publicado: (2021)

Primary cardiac angiosarcoma diagnosed in the first trimester of pregnancy
por: Burns, Ethan A, et al.
Publicado: (2019)

The Latest Advancement in Pancreatic Ductal Adenocarcinoma Therapy: A Review Article for the Latest Guidelines and Novel Therapies
por: Elsayed, Marwa, et al.
Publicado: (2021)

Transplant Oncology: An Emerging Discipline of Cancer Treatment
por: Abdelrahim, Maen, et al.
Publicado: (2023)

Molecular Signatures of KRAS-Mutated Lung Adenocarcinoma: Analysis of Concomitant EGFR, ALK, STK11, and PD-L1 Status
por: Hsu, Jim, et al.
Publicado: (2022)

Outcomes and prognostic contributors in patients with KRAS mutated non-small cell pulmonary adenocarcinomas: a single institution experience
por: Burns, Ethan A., et al.
Publicado: (2021)

Pembrolizumab
por: Khoja, Leila, et al.
Publicado: (2015)

RNAi and cancer: Implications and applications
por: Abdelrahim, Maen, et al.
Publicado: (2006)

Consuming Genistein Improves Survival Rates in the Absence of Laxative in ΔF508-CF Female Mice
por: Lord, Ryan, et al.
Publicado: (2018)

Thymoquinone’s Antiviral Effects: It is Time to be Proven in the Covid-19 Pandemic Era and its Omicron Variant Surge
por: Abdelrahim, Maen, et al.
Publicado: (2022)

Immune Checkpoint Inhibitor-Related Adverse Cardiovascular Events in Patients With Lung Cancer
por: Chitturi, Kalyan R., et al.
Publicado: (2019)

Pembrolizumab for all
por: Kim, Myung S., et al.
Publicado: (2022)

Readministration of Pembrolizumab after Treatment of Tuberculosis Activated by Initial Pembrolizumab Therapy
por: Murakami, Shuji, et al.
Publicado: (2020)

Pembrolizumab in the treatment of metastatic non-small-cell lung cancer: patient selection and perspectives
por: Somasundaram, Ashwin, et al.
Publicado: (2017)

Into the Clinic With Nivolumab and Pembrolizumab
por: Shu, Catherine A., et al.
Publicado: (2016)

Pembrolizumab-associated sarcoidosis
por: Cotliar, Jonathan, et al.
Publicado: (2016)

Pembrolizumab-induced pneumonitis
por: Leroy, Vincent, et al.
Publicado: (2017)

Response to lenvatinib and pembrolizumab combination therapy in pembrolizumab-pretreated relapsed endometrial cancer
por: Mimura, Kaito, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_1fqnp21otk4v35dbvr67t00mkb